About - BNTX :

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Employees - 6133, CEO - Dr. Ugur Sahin M.D., Sector - Healthcare, Country - DE, Market Cap - 27.11B

Altman ZScore(max is 10): 7.03, Piotroski Score(max is 10): 3, Working Capital: $15963700000, Total Assets: $22401200000, Retained Earnings: $18838500000, EBIT: -580303556, Total Liabilities: $3286700000, Revenue: $3040100000

AryaFin Target Price - $-63.85 - Current Price $113.08 - Analyst Target Price $135.39

Stats & Key Metrics
TickerBNTX
Index-
Curent Price 113.08
Change1.56%
Market Cap27.11B
Average Volume861.25K
Income-501.56M
Sales3.30B
Book Value/Share88.98
Cash/Share77.78
Dividend Est-
Dividend TTM-
Dividend Ex-DateJun 02, 2022
Employees3082
Moving Avg 20days-3.57%
Moving Avg 50days-0.15%
Moving Avg 200days15.05%
Shares Outstanding239.74M
Earnings DateNov 04 BMO
Inst. Ownership19.48%
Key Ratios & Margins
Price/Earnings-
Forwad P/E-
PE Growth-
Price/Sales8.21
Price/Book1.27
Price/Cash1.45
Price/FCF18.34
Quick Ratio7.21
Current Ratio7.33
Debt/Equity0.01
Return on Assets-2.07%
Return on Equity-2.37%
Return on Investment-2.33%
Gross Margin84.31%
Ops Margin-8.08%
Profit Margin-15.20%
RSI47.60
BETA(β)0.18
From 52week Low47.76%
From 52week High-14.00%
Earnings & Valuation
EPS-2.15
EPS next Year-3.48
EPS next Qtr0.50
EPS this Year-183.96%
EPS next 5 Year-
EPS past 5 Year-
Sales past 5 Year843.27%
EPS Y/Y-118.03%
Sales Y/Y-52.11%
EPS Q/Q22.07%
Sales Q/Q40.41%
Sales Surprise141.90%
EPS Surprise152.75%
ATR(14)5.17
Perf Week-6.06%
Perf Month10.71%
Perf Quarter0.03%
Perf Year10.00%
Perf YTD7.14%
Target Price135.39

AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer